Analysis reveals a signaling axis involving TBX2 and LILRB4+ myeloma-initiating cells, suggesting new therapeutic avenues.
Key Points
Identified TBX2 as a transcription factor involved in LILRB4+ myeloma-initiating cells, highlighting its potential role in multiple myeloma.
Established a comprehensive cellular hierarchy for multiple myeloma based on normal plasma cell development, enabling the identification of key cell populations.
Utilized single-cell transcriptomic analysis and epigenetic drug screening to evaluate the effects of targeting TBX2 and LILRB4 on myeloma cells.
Findings indicate that targeting the TBX2-LILRB4 axis could provide novel differentiation-based therapies for resistant multiple myeloma cells.